Literature DB >> 17329910

Characterization of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, and meropenem as substrates of human renal transporters.

Takahiro Shibayama1, Daisuke Sugiyama, Emi Kamiyama, Taro Tokui, Takashi Hirota, Toshihiko Ikeda.   

Abstract

To characterize the renal handling of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, and meropenem in humans, we examined their affinities as substrates to human renal transporters. In vitro studies on the uptake of [14C]CS-023 and [14C]meropenem were conducted using HEK293 cells expressing human organic anion transporters (hOAT) 1, hOAT3, hOAT4, and the human organic cation transporters (hOCT) 1 and hOCT2. CS-023 did not serve as the substrate for any of the transporters tested. On the other hand, meropenem was transported by hOAT1 and hOAT3. The Km value of the hOAT3-mediated transport was 847 microM, and the uptake was inhibited by probenecid, p-aminohippurate and benzylpenicillin with Ki values of 3.76, 712, and 202 microM, respectively. One of the reasons why CS-023 is not a substrate of hOATs, and vice versa for meropenem, would be that a very small proportion of CS-023 exists as the anionic form at the physiological pH, whereas 50% of meropenem exists as the anionic form. These findings indicate that the lack of recognition of CS-023 by renal transporters is one of the reasons for its long plasma half-life in humans compared with meropenem which undergoes renal tubular secretion mediated by hOAT1 and hOAT3.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17329910     DOI: 10.2133/dmpk.22.41

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  8 in total

Review 1.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

2.  Determining the Effects of Chronic Kidney Disease on Organic Anion Transporter1/3 Activity Through Physiologically Based Pharmacokinetic Modeling.

Authors:  Samuel Dubinsky; Paul Malik; Dagmar M Hajducek; Andrea Edginton
Journal:  Clin Pharmacokinet       Date:  2022-05-05       Impact factor: 5.577

3.  In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.

Authors:  Kaori Tanaka; Hiroshige Mikamo; Kenichi Nakao; Taku Ichiishi; Takatsugu Goto; Yuka Yamagishi; Kunitomo Watanabe
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

4.  Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.

Authors:  Navita L Mallalieu; Siân Lennon; Mei Liu; Christopher Kirkpatrick; Richard Robson; Eric Luedin; Brian E Davies
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

Review 5.  Assessment of the role of renal organic anion transporters in drug-induced nephrotoxicity.

Authors:  Yohannes Hagos; Natascha A Wolff
Journal:  Toxins (Basel)       Date:  2010-08-09       Impact factor: 4.546

6.  Physiologically Based Pharmacokinetic Modeling of Meropenem in Preterm and Term Infants.

Authors:  Samit Ganguly; Andrea N Edginton; Jacqueline G Gerhart; Michael Cohen-Wolkowiez; Rachel G Greenberg; Daniel Gonzalez
Journal:  Clin Pharmacokinet       Date:  2021-06-22       Impact factor: 5.577

7.  Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.

Authors:  Lisa Ehmann; Michael Zoller; Iris K Minichmayr; Christina Scharf; Barbara Maier; Maximilian V Schmitt; Niklas Hartung; Wilhelm Huisinga; Michael Vogeser; Lorenz Frey; Johannes Zander; Charlotte Kloft
Journal:  Crit Care       Date:  2017-10-21       Impact factor: 9.097

8.  Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis.

Authors:  Renata Černá Pařízková; Jiřina Martínková; Eduard Havel; Petr Šafránek; Milan Kaška; David Astapenko; Jan Bezouška; Jaroslav Chládek; Vladimír Černý
Journal:  Crit Care       Date:  2021-07-17       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.